U.S., April 14 -- ClinicalTrials.gov registry received information related to the study (NCT07523711) titled 'Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity' on April 06.

Brief Summary: The primary objective of the trial is to evaluate the effect of maridebart cafraglutide on the pharmacokinetics (PK) of a combined oral contraceptive (COC) in postmenopausal female participants living with overweight or obesity.

Study Start Date: April 09

Study Type: INTERVENTIONAL

Condition: Overweight Obesity

Intervention: DRUG: COC

Administered orally.

DRUG: Maridebart Cafraglutide

Administered as SC injection.

Recruitmen...